dokumendiregister.ee
Sissetulev kiriAvalik

Küsimused

Ravimiamet · 16. juuli 2024
Viit
JUH-8/2579-1
Registreeritud
16. juuli 2024
Dokumendi liik
Sissetulev kiri
Adressaat
Thomson Reuters Corporation
Saabumis/saatmisviis
e-post
Funktsioon
JUH Juhtimine
Sari
JUH-8 Kirjavahetus pressiga
Toimik
JUH-8/2024
Vastutaja
Carmen Katariina Sikk (RA)
Lahendamise tähtaeg
31. juuli 2024

Failid

Sisu (failidest)

Saatja: "Carmen Katariina Sikk" <[email protected]> Saaja: "Kärolin Jenas" <[email protected]> Teema: Ed: Journalist query - semaglutide Kuupäev: 2024-07-03 06:28 Saatja: Silver, Andrew (Reuters) <[email protected]> Saatmisaeg: esmaspäev, 1. juuli 2024 18:19 Adressaat: Carmen Katariina Sikk <[email protected]> Teema: Journalist query - semaglutide Hi I’m a journalist with Reuters in Shanghai, I write about health and pharma. I’ve heard there may be some countries where there is no patent on semaglutide. Do you know if any companies in those countries are producing oral pill or injectible versions of semaglutide drugs (i.e. rybelsus generic/biosimilar) for consumers that are sold to people based in countries with patent protection (i.e. directly or via third-party distributors) like Estonia, and are there any examples you can share? Or how common such a phenomenon is, what countries are involved? Appreciate your time, -Andrew
Allikas: Ravimiamet dokumendiregister →